Compounds > 7-hydroxy-2-n,n-dipropylaminotetralin
Page last updated: 2024-10-21

7-hydroxy-2-n,n-dipropylaminotetralin and Atherosclerotic Parkinsonism

7-hydroxy-2-n,n-dipropylaminotetralin has been researched along with Atherosclerotic Parkinsonism in 2 studies

7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's1 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ueda, H1
Sato, K1
Okumura, F1
Misu, Y1
Bordet, R1
Ridray, S1
Schwartz, JC1
Sokoloff, P1

Other Studies

2 other studies available for 7-hydroxy-2-n,n-dipropylaminotetralin and Atherosclerotic Parkinsonism

ArticleYear
L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats.
    Brain research, 1995, Nov-06, Volume: 698, Issue:1-2

    Topics: Acetylcholine; Analysis of Variance; Animals; Corpus Striatum; Disease Models, Animal; Dopamine Agon

1995
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats.
    The European journal of neuroscience, 2000, Volume: 12, Issue:6

    Topics: Animals; Antiparkinson Agents; Benzazepines; Binding, Competitive; Corpus Striatum; Denervation; Diz

2000